 CAMBRIDGE, Mass.--BUSINESS WIRE--- ALVR ASH20--AlloVir Nasdaq: ALVR, a late clinical-stage cell therapy company, today announced that preclinical data presented in an oral presentation at the 62nd American Society of Hematology ASH Annual Meeting, demonstrates selective antiviral activity of ALVR109 the companys virus-specific T cell therapy designed to combat SARS-CoV-2, the virus responsible for COVID-19. The data presented found that the SARS-CoV-2 virus-specific T cell therapy, ALVR109, was able 